15					
			13	Ŷ ГП	
Please ty	pe a plus sig	n (+) inside i	ihla bo		٠.

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

. . .

Sheet 1

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

: (use as many sheets as necessary) of 2

	Complete If Known
Application Number	new Application 10/132, 734
Filing Date	not yet assigned 72/632,734
First Named Inventor	Weikert, et al.
Group Art Unit	unassigned /624
Examiner Name	unassigned KIKLE
Attorney Docket Number ·	R0087B-REG

	. 1. 6		U.S. PATENT DOCL	IMENTS	
Examiner Initials	Cite No.	Number (If known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columna, Lines, Where Relevant Passages or Relevant Figures Appear
BK	AI.	5,382,595	Minami et al.	Jan. 17, 1995	
AK	A2	5,177,089	Minami et al.	Jan. 5, 1993	
A.K.	A3	5,047,417	Minami et al.	Sept. 10, 1991	
B.K.	A4	5,607,953	Minami et al.	Mar. 4, 1997	611
B.K.	A5	4,748,182	Hilbert et al.	May 31, 1988	
13:16.	A6.	4,880,802	Schohe et al.	Nov. 14, 1989	
A.K.	A7	5,298,513	Schohe et al.	Mar. 29, 1994	
D.K.	A8	4,584,293	Reiffen et al.	Apr. 22, 1986	
s.K.	A9	5,118,704	Minaskanian et al.	Jun. 2, 1992	
D.K.	A10	5,545,755	Lin et al.	Aug. 13, 1996	

	77.			FOREIG	N PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Office <sup>3</sup>		ment Ind Code <sup>5</sup> If known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T,
1K	B1	WO	99/43657	PCT	F.Hoffmann-La Roche	Sept., 2 1999	- "	
- 1								

Examiner Signature	Bruk	2//	Date Considered	12/11/03	

EXAMINER: Initial if reference considered, whether or an idiation is in conformance with MPEP 609; Draw line through citation in not in conformance and not considered, include copy of this form with next communication to applicant.

Burden How Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Critel Information Officer, U.S. Patient and Trademark Office, Washington, DC 20231, DO NOT SENG FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Doc.#113580

<sup>1</sup> Unique citation designation number, 2 See attached Kinds of U.S. Patent Documents, 2 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the Indication of the year of the refign of the Emperor must precede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \* Applicant is to place a check mark hee if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are Complete if Known Application Number New Application 10/632,734

INFORMATION DISCLOSURE Filing Date not yet assigned . STATEMENT BY APPLICANT Welkert, et al. First Named Inventor unassigned /62 4 Group Art Unit (use as many sheets as necessary) unassigned KIFLE Examiner Name of 2 R0087B-RFG Attorney Docket Number.

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т.
B.K.	C1	HOMAN et al., "Structural Analogues of 5-Ome-BPAT; Synthesis and Interactions with Dopamine D <sub>2</sub> , D <sub>3</sub> , and Serotenin 5-HT <sub>1A</sub> Receptors", <u>Bloorg, Med. Chem.</u> , (1999), pp. 1111-1121, vol. 7(6)	
BK.	C2	GLENNON et al, "N-(Phthalimidoalkyl) Derivatives of Serotonergic Agents: A Common Interaction at 5-HT <sub>IA</sub> Serotonin Binding Sites?", <u>J.Med. Chem.</u> , (1989), pp. 1921-1926; vol. 32	
DK.	СЗ	EHLERT, et al., "Subtypes of the Muscarinic Receptor in Smooth Muscle", Life Sciences, (Minireview), (1997), pp. 1729-1740, vol. 61, No. 18	
B.K	C4	HEDGE, et al., "Muscarinic Receptor Subtypes Modulating Smooth Muscle Contractility in the Uninary Bladder", Life Sciences, (1999), pp. 419-428, 64, Nos. 6/7	
DK	C5	EGLEN, et al., "Muscarinic acetylcholine receptor subtypes in smooth muscle", <u>Trends.</u> <u>Pharmacol. Sci.</u> , (1994), pp. 114-119, vol. 15	
D.K.	C6	EGLEN, et al, "Muscarinic receptor subtypes and smooth muscule function", Pharmacol, Rev., (1996), pp. 531-565, vol. 48, No.4	
Ŋ.K.	<b>C</b> 7	NILVEBRANT, et al., "Tolterodine — A new Bladder Selective Muscarinic Receptor Antagonist: Preclinical Pharmacological and Clinical Data", <u>Life Sciences</u> , (1997), pp. 1129-1136, vol. 60	. 4
B.K.	C8	ALABASTER, "Discovery & Development of Selective Ms Antagonists for Clinical Use", Life Sciences, (1997), pp. 1053-1060, vol. 60, Nos. 13/14	
D.K.	C9	OSAYU, et al, "Urinary Bladder-selective Action of the New Antimuscarinic Compound Vamicamide", <u>Drug Res.</u> , (1994) , pp. 1242-1249, vol. 44(II), No. 11	٠.,
OK.	C10	HOMMA, et al, "Randomized Double-Blind Study to Compare Clinical Efficacy of Temiverine and Propiverine for Unstable Bladder and Detrusor Hyperreflexia", Neurology and Urodynamics,—Abstract, (1997), pp. 345-346, vol. 16	
116	C11	EGLEN AND HEGDE, "Selective modulation of muscarinic receptor subtypes: therapeutic potential", Emerging Drugs, - Chapter 4, (1998), pp. 67-79, vol. 3, Ashley Publications	
P.K.	C12	EGLEN, et al, "Muscarinic receptor ligands and their therapeutic potential", <u>Curr. Opin.</u> Chem. Biol. (1999), pp. 426-432, vol. 3, Elsevier Science	
D.K.	C13	CAULFIELD, et al, "International Union of Pharmacology, XVII. Classification of Muscarinic Acetylcholine Receptors", Pharmacological Reviews, (1998), pp. 279-290, vol. 50(2)	

Signature / Sunt / Considered / C/18/03
---